Journal
Cell Reports
Publication Date
4-26-2022
Volume
39
Issue
4
First Page
110733
Document Type
Open Access Publication
DOI
10.1016/j.celrep.2022.110733
Rights and Permissions
Martino MR, Gutiérrez-Aguilar M, Yiew NKH, Lutkewitte AJ, Singer JM, McCommis KS, Ferguson D, Liss KHH, Yoshino J, Renkemeyer MK, Smith GI, Cho K, Fletcher JA, Klein S, Patti GJ, Burgess SC, Finck BN. Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids. Cell Rep. 2022 Apr 26;39(4):110733. doi: 10.1016/j.celrep.2022.110733. Erratum in: Cell Rep. 2022 Nov 15;41(7):111633. Copyright 2022 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Martino, Michael R.; Gutiérrez-Aguilar, Manuel; Yiew, Nicole K. H.; Lutkewitte, Andrew J.; Singer, Jason M.; McCommis, Kyle S.; Ferguson, Daniel; Liss, Kim H. H.; Yoshino, Jun; Renkemeyer, M. Katie; Smith, Gordon I.; Cho, Kevin; Fletcher, Justin A.; Klein, Samuel; Patti, Gary J.; Burgess, Shawn C.; and Finck, Brian N., "Silencing alanine transaminase 2 in diabetic liver attenuates hyperglycemia by reducing gluconeogenesis from amino acids." Cell Reports. 39, 4. 110733 (2022).
https://digitalcommons.wustl.edu/oa_4/1637
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
Erratum
